menu toggle

Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected

Generics Bulletin, Brian Biehn

Discussing the latest developments in the US biosimilars market, AmerisourceBergen's senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors. 

For the full interview, please visit Generics Bulletin